Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa

Accesswire March 7, 2022

Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia

Accesswire March 3, 2022

Moderna to Present at Upcoming Conferences in March 2022

Accesswire March 2, 2022

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

PR Newswire February 28, 2022

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

GlobeNewswire February 28, 2022

Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna

GlobeNewswire February 28, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union

Accesswire February 24, 2022

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates

Accesswire February 24, 2022

Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

Business Wire February 23, 2022

Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America

Accesswire February 22, 2022

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data

Accesswire February 22, 2022

Moderna Expands Its mRNA Pipeline with Three New Development Programs

Accesswire February 18, 2022

Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)

Accesswire February 16, 2022

Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries

Accesswire February 16, 2022

Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years

Accesswire February 16, 2022

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries

Accesswire February 15, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

PR Newswire February 15, 2022

Javara Contributes to RSV Prevention Vaccine Trial in Collaboration with Privia Health and Moderna

PR Newswire February 14, 2022

Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering

Accesswire February 9, 2022

Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine

Accesswire February 8, 2022